Conatus Pharmaceuticals Inc CNAT 55.59% announced top-line results from its Phase 2b study, dubbed ENCORE-NF clinical trials, of emricasan in patients with biopsy-confirmed nonalcoholic steatohepatitis, or NASH, and liver fibrosis, showing the trial did not meet the primary endpoint of bringing out one or more than one CRN fibrosis stage improvement with no worsening of steatohepatitis compared with placebo at week 72.
However, the company said it demonstrated biomarker activity across a broad spectrum of liver disease, warranting continued evaluation in more-advanced stage NASH cirrhosis patients.
emricasan verfehlt primäre Endpunkte in mid-stage Studie (Phase 2b)
emricasan wird nicht weiter entwickelt
40% der Angestellten werden gekündigt
Restrukturierung geplant
strategische Optionen werden geprüft
Damit wurde meine skeptische Frage aus dem Posting #111 beantwortet ob sich hier ein Einstieg lohnt.
"The company has updated its financial guidance and is projecting a year-end 2019 net balance of cash, cash equivalents and marketable securities of between $10 million and $15 million."
Thread abonnieren
